Keywords: هرثپین; Adjuvant; Breast cancer; HER2/neu; Herceptin; Subcutaneous; Trastuzumab;
مقالات ISI هرثپین (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: هرثپین; Breast cancer; Hippocrates; Tamoxifen; Angelina Jolie; Herceptin; Radical mastectomy; Mammography; Aromatase inhibitors; BRCA1 and BRCA2; ER; HER2; Triple negative breast cancer (TNBC);
Keywords: هرثپین; Cisplatin; PAMAM dendrimers; Diglycolamic acid; Herceptin; Targeted drug delivery; Apoptosis; Anti-tumor activity;
Keywords: هرثپین; Mesoporous silica nanoparticles; Ultrasound; Contrast agent; Breast cancer; Drug delivery; Herceptin;
A Randomized Phase I Study Comparing the Pharmacokinetics of HD201, a Trastuzumab Biosimilar, With European Union-sourced Herceptin
Keywords: هرثپین; biosimilars; breast cancer; Herceptin; pharmacokinetics; trastuzumab;
No Acute Changes in LVEF Observed With Concurrent Trastuzumab and Breast Radiation With Low Heart Doses
Keywords: هرثپین; Breast; Cardiac toxicity; Herceptin; Radiation; Trastuzumab;
Tumor cryoablation in combination with natural killer cells therapy and Herceptin in patients with HER2-overexpressing recurrent breast cancer
Keywords: هرثپین; Tumor cryoablation; Natural killer cells; Herceptin; Combination treatment; Progression free survival;
Original ResearchEfficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study
Keywords: هرثپین; Breast cancer; HER2/neu; Herceptin; Patient preference; Subcutaneous; Trastuzumab;
Duration of adjuvant trastuzumab in HER2 positive breast cancer: Overall and disease free survival results from meta-analyses of randomized controlled trials
Keywords: هرثپین; HER2; Breast cancer; Trastuzumab; Herceptin; Duration; Adjuvant;
Role of Runx2 in breast cancer-mediated bone metastasis
Keywords: هرثپین; Runx2; runt-related transcription factor 2; BRC; breast cancer gene; HER; herceptin; ER; estrogen; PR; progesterone; ECM; extra cellular matrix; EMT; epithelial mesenchymal transition; JAK/STAT; Janus Kinase; NFκB; nuclear factor kappa-B; MMP; matrix met
Herceptin-functionalized pure paclitaxel nanocrystals for enhanced delivery to HER2-postive breast cancer cells
Keywords: هرثپین; Paclitaxel; Nanocrystals; Herceptin; HER2-positve breast cancer; Tumor-targeting;
HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-up
Keywords: هرثپین; Herceptin; Neoadjuvant chemotherapy; Pathological complete response; Subcutaneous; Trastuzumab;
Enhanced delivery of Paclitaxel using electrostatically-conjugated Herceptin-bearing PEI/PLGA nanoparticles against HER-positive breast cancer cells
Keywords: هرثپین; Targeted delivery; Electrostatic attraction; Herceptin; Paclitaxel; Polyethylenimine;
Herceptin® (trastuzumab) par voie sous-cutanée : une mini révolution ? Ãtude pharmaco-économique
Keywords: هرثپین; Herceptin; Sous-cutanée; Pharmaco-économique; Herceptin; Subcutaneous; Pharmaco-economic;
Biological evaluation of a novel Herceptin-platinum (II) conjugate for efficient and cancer cell specific delivery
Keywords: هرثپین; Platinum drugs; Drug delivery; Herceptin; ELISA; In vitro cytotoxicity
A fluorescence in situ hybridization (FISH) microfluidic platform for detection of HER2 amplification in cancer cells
Keywords: هرثپین; Bio-MEMS; Bio-micro-electro-mechanical-systems; CEP17; Chromosome 17 centromere; CGMH; Chang Gung medical hospital; DNA; deoxyribonucleic acid; DAPI; 4â²-diamidino-2-phenylindole; FISH; fluorescence in situ hybridization; HER2; human epidermal growth fac
Targeted antitumor efficacy and imaging via multifunctional nano-carrier conjugated with anti-HER2 trastuzumab
Keywords: هرثپین; NIR imaging; Herceptin; Active targeting; Doxorubicin; Pluronic;
HER2 testing in gastric and gastroesophageal junction adenocarcinomas
Keywords: هرثپین; FDA; gastric cancer; gastroesophageal junction adenocarcinoma; HER2; HercepTest; Herceptin; immunohistochemistry validation; ToGA; trastuzumab
Targeting HER2Â + breast cancer cells: Lysosomal accumulation of anti-HER2 antibodies is influenced by antibody binding site and conjugation to polymeric nanoparticles
Keywords: هرثپین; Antibody; Herceptin; Antibody-drug conjugate; Nanoparticle;
Comparative evaluation of novel biodegradable nanoparticles for the drug targeting to breast cancer cells
Keywords: هرثپین; Nanoparticles; Polyesterurethanes; Herceptin; Paclitaxel; Cancer targeting
HER2 Assessment in Upper Gastrointestinal Tract Adenocarcinoma
Keywords: هرثپین; HER2; Trastuzumab; Herceptin; Esophageal adenocarcinoma; Gastric adenocarcinoma;
Breast cancer
Keywords: هرثپین; adjuvant therapy; biological markers; breast cancer; Herceptin; oncoplastic; sentinel node biopsy
Anti-KDEL-coated nanoparticles: A promising tumor targeting approach for ovarian cancer?
Keywords: هرثپین; Nanoparticle; Targeting; Ovarian cancer; GRP78; GRP94; DiO; dioctadecyloxacarbo-cyanine perchlorate; EDAC; 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimidide; ER; endoplasmic reticulum; GRP; glucose-regulated protein; HER; herceptin; mAb; monoclonal antibod
Comparing the intracellular fate of components within a noncovalent streptavidin nanoparticle with covalent conjugation
Keywords: هرثپین; Nanoparticle; Antisense oligomer; Herceptin; Streptavidin;
The debate about the funding of Herceptin: A case study of 'countervailing powers'
Keywords: هرثپین; Herceptin; Countervailing powers; Medication controversies; New Zealand; Pharmaceutical companies; Regulators; Health consumer groups; Media;
Novel method for differentiation between Trastuzumab and host adaptive response
Keywords: هرثپین; HER-2; Adaptive; Herceptin; Screening; Cancer; Antibody;
Herceptin, a recombinant humanized anti-ERBB2 monoclonal antibody, induces cardiomyocyte death
Keywords: هرثپین; Herceptin; Trastuzumab; ERBB2; Cardiomyocyte; Apoptosis;
Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer
Keywords: هرثپین; Herceptin; T-DM1; Maytansine; Antibody–drug conjugate; Trastuzumab resistanceADCC, antibody-dependent cellular cytotoxicity; BAC, bacterial artificial chromosome; BSA, bovine serum albumin; GAHIG, goat anti-human immunoglobulin; FISH, fluorescence in situ
Growth differentiation factor 15 (GDF15)-mediated HER2 phosphorylation reduces trastuzumab sensitivity of HER2-overexpressing breast cancer cells
Keywords: هرثپین; Breast cancer; erbB2; Herceptin; Resistance; Trastuzumab; Lapatinib;
Enhanced antiproliferative activity of Herceptin (HER2)-conjugated gemcitabine-loaded chitosan nanoparticle in pancreatic cancer therapy
Keywords: هرثپین; Gemcitabine; Targeted drug delivery; Herceptin; Chitosan nanoparticles; Pancreatic cancer;
177Lu labeling of Herceptin and preclinical validation as a new radiopharmaceutical for radioimmunotherapy of breast cancer
Keywords: هرثپین; Biodistribution; breast cancer; Lutetium-177; Herceptin; DOTA; Cytotoxicity
Targeted near-IR QDs-loaded micelles for cancer therapy and imaging
Keywords: هرثپین; Near-IR QDs; Herceptin; Tumor imaging; Nano-probes
A strategy for precision engineering of nanoparticles of biodegradable copolymers for quantitative control of targeted drug delivery
Keywords: هرثپین; Biodegradable copolymers; Cancer nanotechnology; Docetaxel; Drug targeting; Herceptin; Nanomedicine
Herceptin and breast cancer: An overview for surgeons
Keywords: هرثپین; Breast cancer; Herceptin; Trastuzumab; Morbidity; Mortality; Recurrence; Evidence
Mannose addition by yeast Pichia Pastoris on recombinant HER-2 protein inhibits recognition by the monoclonal antibody herceptin
Keywords: هرثپین; Yeast; HER-2; Herceptin; Glycosylation
Development and validation of cell-based ELISA for the quantification of trastuzumab in human plasma
Keywords: هرثپین; ELISA, Enzyme-Linked Immunosorbent Assay; TBS, Tris Buffered Saline; HRP, Horseradish peroxidiseTrastuzumab; Herceptin; Pharmacokinetics; Breast cancer; Cell-based ELISA
The bioanalysis of the monoclonal antibody trastuzumab by high-performance liquid chromatography with fluorescence detection after immuno-affinity purification from human serum
Keywords: هرثپین; Monoclonal antibody; Trastuzumab; Herceptin; Immuno-affinity purification; HPLC-fluorescence
Activation of KATP channels increases anticancer drug delivery to brain tumors and survival
Keywords: هرثپین; Potassium channel; Blood-brain barrier; Minoxidil sulfate; Glioblastoma multiforme; Temozolomide; Herceptin
Radiolabeling of trastuzumab with 177Lu via DOTA, a new radiopharmaceutical for radioimmunotherapy of breast cancer
Keywords: هرثپین; Radioimmunotherapy; Breast cancer; Trastuzumab; Herceptin; Lutetium-177; DOTA
Development and validation of an enzyme-linked immunosorbent assay for the quantification of trastuzumab in human serum and plasma
Keywords: هرثپین; ELISA; Trastuzumab; Herceptin; Anti-idiotype
The bioanalysis of trastuzumab in human serum using precipitate-enhanced ellipsometry
Keywords: هرثپین; PEIA; Ellipsometry; Trastuzumab; Herceptin; Immunoassay
In vivo monitoring of intranuclear p27kip1 protein expression in breast cancer cells during trastuzumab (Herceptin) therapy
Keywords: هرثپین; Herceptin; Radioimmunoconjugates; Tat; Nuclear, p27kip1;
Study of inhibition effect of Herceptin on interaction between Heregulin and ErbB Receptors HER3/HER2 by single-molecule force spectroscopy
Keywords: هرثپین; Epidermal growth factor receptor; Heregulin; Herceptin; Atomic force microscopy; Single-molecule force spectroscopy; Ligand–receptor interaction
The co-delivery of paclitaxel and Herceptin using cationic micellar nanoparticles
Keywords: هرثپین; Co-delivery; Herceptin; Paclitaxel; Cationic micellar nanoparticles; Amphiphilic copolymer
Direct 99mTc labeling of Herceptin (trastuzumab) by 99mTc(I) tricarbonyl ion
Keywords: هرثپین; Herceptin; HER-2; Trastuzumab; 99mTc(I)-tricarbonyl ion; Breast cancer
Predicting the efficacy of trastuzumab-based therapy in breast cancer: Current standards and future strategies
Keywords: هرثپین; Her-2; Response prediction; Herceptin; ECD; Phospho Her-2
Effect of deleterious nsSNP on the HER2 receptor based on stability and binding affinity with herceptin: A computational approach
Keywords: هرثپین; Breast cancer; SNP; ERBB2 gene; HER2 receptor; Herceptin; RMSD; Stability; Binding energy; Flexibility
HER-2-mediated endocytosis of magnetic nanospheres and the implications in cell targeting and particle magnetization
Keywords: هرثپین; Polypyrrole–Fe3O4 nanospheres; Herceptin; HER-2-mediated endocytosis; Cell targeting; Magnetization
Multifunctional poly(d,l-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer
Keywords: هرثپین; Biodegradable polymers; Cancer nanotechnology; Medical clay; Nanomedicine; Herceptin; HER2
Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: A systematic review
Keywords: هرثپین; Antibodies; Monoclonal; Breast Neoplasms; Early Breast Cancer; Combined Modality Therapy; Trastuzumab; Herceptin; Adjuvant Thearpy; Receptor, erbB-2